[Alirocumab for patients with hypercholesterolemia]
Perelli L, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A
Record ID 32018001522
Spanish
Original Title:
Alirocumab en pacientes con hipercolesterolemia
Authors' recommendations:
CONCLUSIONS
Moderate-quality evidence suggests that adding alirocumab to the lipid-lowering treatment is effective in reducing LDL cholesterol and cardiovascular events as cardiovascular primary prevention in patients with primary hypecholesterolemia (familial or not) or mixed dyslipidemia, who do not reach their treatment goal with the standard lipid-lowering treatment.
High-quality evidence suggests that alirocumab reduces mortality and cardiovascular events in patients with primary hypecholesterolemia or mixed dyslipidemia with a history of recent coronary event, who do not reach their treatment goal with the maximum statin doses.
Most clinical practice guidelines surveyed in the United States, Europe and Latin America, recommend using alirocumab for selected patients with primary hypercholesterolemia (familial or not) or mixed dyslipidemia not reaching their LDL treatment goal in spite of using the maximum lipid-lowering treatment dose with other drugs.
United States and Europe private and public sponsors cover alirocumab for patients who do not reach their treatment goal with the first line of treatment.
No economic studies on alirocumab in Argentina have been found, therefore cost-effectiveness and budget impact of this technology are unknown.
Details
Project Status:
Completed
Year Published:
2019
URL for published report:
https://www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Hypercholesterolemia
- PCSK9 Inhibitors
- Cholesterol, LDL
- Antibodies, Monoclonal, Humanized
- Anticholesteremic Agents
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
<p>Institute for Clinical Effectiveness and Health Policy (IECS)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.